Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642
This examiner grants 62% of resolved cases
Josephine Kebbeh Darpolor is a patent examiner working in Tech Center 1600 and Art Unit 1642. The examiner has completed 29 resolved cases, which form the foundation for the performance data in this profile. The allowance rate for these 29 cases is 62.1 percent. This 62.1 percent rate is a central metric for practitioners to evaluate when their applications are being examined. The 29 resolved cases offer a data set for understanding the examiner's historical patterns in Tech Center 1600.
The median days to allowance for applications that reach a grant is 1289. This 1289-day period represents the middle value of the time from filing to the issuance of a patent for successful cases. Practitioners can use the 1289-day figure to estimate the duration of the prosecution process under this examiner. The 1289-day median is a useful metric for managing the timing of patent portfolio developments. This timeframe is a specific characteristic of the examiner's work within Art Unit 1642.
The profile also features an interview lift of 39.3 percent. This 39.3 percent lift measures the difference in allowance rates between cases with an interview and those without one. Applicants can assess the 39.3 percent lift when determining the strategic value of direct communication with the examiner. The 39.3 percent lift is a data point for those seeking to navigate the examination process effectively. This metric, alongside the 62.1 percent allowance rate, helps define the prosecution environment for the 29 resolved cases.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17791549 | MULTISPECIFIC ANTIBODIES THAT BIND BOTH MAIT AND TUMOR CELLS | Non-Final OA | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) |
| 18571091 | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE | Non-Final OA | Therini Bio, Inc. |
| 18025206 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | Final Rejection | GENMAB A/S |
| 18000674 | CHIMERIC ANTIGEN RECEPTOR TARGETING CLDN18.2 AND USE THEREOF | Non-Final OA | SHANGHAI LONGYAO BIOTECHNOLOGY INC., LTD |
| 17920323 | COMPOSITIONS AND METHODS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME | Non-Final OA | Edesa Biotech Research, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy